The four retained variables—CAD, hypertension, renal insufficiency, and Alb levels—represent interconnected yet distinct pathophysiological pathways contributing to HF risk in elderly RRMM patients receiving carfilzomib therapy. The gene discussed is ALB; the disease is hypertensive disorder.